Clinical Trials on Jaw, Partially Edentulous in Australia

Total 52 results

Dentsply Sirona Implants and Consumables

Completed

Study Comparing OsseoSpeed™ Implants of Two Different Lengths in the Upper and Lower Posterior Jaw

Jaw, Edentulous, Partially

United States, Australia, Netherlands, Sweden, United Kingdom
Institut Straumann AG

Completed

Clinical Study Comparing Submerged Versus Trans-mucosal Healing of P.004 Implants in the Anterior Mandible and Maxilla

Jaw, Edentulous, Partially

Spain, Germany, United States, Australia, Italy, Sweden, Switzerland
Dentsply Sirona Implants and Consumables

Completed

Short Implants - An Alternative to Bone Grafting?

Jaw, Edentulous, Partially

United States, Austria, Poland, Spain, Switzerland
Medical University of Graz
Neoss Ltd., Harrogate, UK

Completed

Two Interforaminal Implants in an Immediate or Delayed Loading Protocol for the Elderly

Edentulous Jaw

Austria
Nobel Biocare

Completed

The TREFOIL Concept 5 Year Clinical Investigation

Edentulous or Failing Dentition Mandible

Italy, United States, Australia, Chile, Spain
LG Chem

Completed

Clinical Study to Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 720 Injected for Jawline Contouring

Jaw Volume Deficit

Austria, Poland
Supernus Pharmaceuticals, Inc.
Melbourne Health

Completed

Bioavailability, Safety, and Tolerability of BIS-001 ER

Epilepsy, Complex Partial

Australia
Sydney Local Health District

Enrolling by invitation

Effects of Class III Elastics on Stability of Orthopaedic Class III Correction

Class III Malocclusion | Underbite

Australia
ZimVie

Completed

Study of Certain Prevail Implants Used to Treat All Types of Edentulism in the Maxilla and Mandible (PrevailMulti)

Partial Edentulism

Austria
Advanced Osteotomy Tools (AOT) AG
Clinical Trial Unit, University Hospital Basel, Switzerland

Completed

First-In-Man Performance and Safety Evaluation of the CARLO® Device in Midface Osteotomies

Abnormalities, Jaw | Malocclusion, Angle Class III

Germany, Austria, Switzerland
Medical University Innsbruck

Completed

The Influence of Wedge Insoles After Partial Meniscectomy

Partial Meniscectomy

Austria
Ascend Biopharmaceuticals Ltd

Completed

Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor

Basal Cell Nevus Syndrome | Basal Cell Carcinoma

Australia
Medical University of Graz

Enrolling by invitation

Local and Systemic Changes in Osteonecrosis of the Jawbone (SULVO)

Osteonecrosis of the Jaw

Austria
Medical University of Graz

Completed

Apicoectomy Longterm Results

Periapical Diseases

Austria
Genovate-NaviFUS (Australia) Pty Ltd.
Genovate Biotechnology Co., Ltd.,; NaviFUS Corporation

Recruiting

Evaluation of the NaviFUS System in Drug Resistant Epilepsy

Drug Resistant Epilepsy | Epilepsy, Temporal Lobe

Australia
Pfizer

Completed

Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

Seizure Disorder, Partial

Australia, Spain, Portugal, United Kingdom, Canada, Belgium, Germany, Poland, Netherlands, Austria
Pfizer

Completed

To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

Seizure Disorder, Partial

Spain, France, Italy, Australia, United Kingdom, Germany, Belgium, Netherlands, Austria, Sweden, Finland, South Africa, Switzerland
UCB Pharma

Terminated

Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide (VICTOR)

Epilepsy, Partial

Austria, Germany, Spain
Ascend Biopharmaceuticals Ltd

Completed

A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma (ASN-002-001)

Basal Cell Nevus Syndrome | Skin Neoplasm | Nodular Basal Cell Carcinoma of Skin

Australia
Institut Straumann AG

Completed

Evaluation of Immediate Versus Delayed Loading of Dental Implants With a Modified Surface

Partial Edentulism

United States, Austria, Germany, Ireland, Netherlands, Portugal, Spain, Sweden, Switzerland
Cerebral Therapeutics LLC

Terminated

Anti-Epilepsy Medication Valproate Administered Via ICV Route and Catheters and Pumps for CSF Infusion

Focal Epilepsy

Israel, Australia
Novartis Pharmaceuticals

Completed

A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients

Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients

Austria, Switzerland
Bial - Portela C S.A.

Completed

Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children

Partial Epilepsy in Children and Adolescents

United Kingdom, Spain, Serbia, Italy, Austria, Bosnia and Herzegovina, Croatia, Czechia, France, Germany, Hungary, Malaysia, Moldova, Republic of, Philippines, Poland, Portugal, Romania, Russian Federation, Slovakia, Taiwan, Ukr...
Medical University of Graz

Completed

Use of an SPF30 Sunscreen and an After-sun-lotion in Skin Cancer Risk Patients

Skin Cancer | Basal Cell Nevus Syndrome | Xeroderma Pigmentosum

Austria
Pfizer

Completed

Pregabalin Open-Label Extension Trial in Patients With Partial Seizures

Epilepsies, Partial | Epilepsy, Complex Partial

Spain, France, Canada, Germany, Italy, Lithuania, Austria, United Kingdom
Eisai Inc.

Completed

A Double-blind Study to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy

Epilepsy

Australia, France, Poland, Germany, Spain, India, Serbia, Greece, Korea, Republic of, Russian Federation, Taiwan, Hungary, Italy, Sweden, Denmark, Slovakia, United Kingdom, South Africa
UCB Pharma

Completed

Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures

Partial Epilepsies

United States, Austria, Bulgaria, Czechia, Denmark, Finland, France, Greece, Italy, Mexico, Romania, Russian Federation, Spain, Switzerland, Turkey
SK Life Science, Inc.

Recruiting

Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

Partial Epilepsy

United States, Spain, Korea, Republic of, Germany, Australia, Poland, Hungary
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Nevoid Basal Cell Carcinoma Syndrome | Basal Cell Carcinoma | Gorlin Syndrome

Belgium, Austria, Germany, Canada
UCB Pharma

Completed

Assess Safety and Efficacy of Lacosamide in Patients With Partial Seizures

Epilepsy

France, Poland, United Kingdom, Germany, Spain, Finland, Australia, Russian Federation, Hungary, Lithuania, Sweden, Czechia, Croatia
SK Life Science, Inc.

Completed

A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Partial Epilepsy

Australia, United States, Korea, Republic of, Germany, Hungary, Serbia, Bulgaria, Czechia, France, Israel, Poland, Romania, Spain, Thailand, Ukraine
SK Life Science, Inc.

Completed

Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Partial Epilepsy

United States, Spain, Korea, Republic of, Serbia, Germany, Bulgaria, Argentina, Australia, Chile, Czechia, Hungary, Mexico, Poland, Russian Federation, Sweden, Thailand, Ukraine
Marinus Pharmaceuticals

Completed

Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension

Drug Resistant Partial Onset Seizure

United States, Australia, Russian Federation, Bulgaria, Germany, Poland
NYU Langone Health
The Epilepsy Study Consortium

Completed

The Human Epilepsy Project (HEP)

Focal Epilepsy

United States, Canada, Australia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures

Epilepsy | Seizures | Partial Seizure Disorder

United States, Australia, France, Belgium, Taiwan, Spain, Argentina, Poland, India, Ukraine, Finland, Korea, Republic of, Russian Federation, Chile, Thailand, Hungary, Israel, New Zealand, Canada, Mexico, Norway, Netherlands, South...
Novartis

Withdrawn

Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures

Partial Onset Seizures

United States, Austria, Spain, Estonia, Bulgaria, Latvia, Canada, India, Belgium, Lithuania, Romania
Eisai Inc.

Completed

Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Refractory Partial Seizures

Hong Kong, Italy, Australia, Spain, Portugal, Taiwan, India, Thailand, Hungary, Poland, Bulgaria, Serbia, Russian Federation, Korea, Republic of, Ukraine, Romania, Latvia, Lithuania, Germany, Estonia, Czech Republic, Philippines, Ma...
Eisai Inc.

Completed

A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)

Partial Onset Seizures

Germany, Sweden, Norway, Austria, Denmark
Eisai Inc.

No longer available

An Extended Access Program for Perampanel

Partial Onset Seizures

Italy, Spain, Belgium, Israel, Poland, Taiwan, Czechia, Finland, Thailand, Malaysia, Argentina, Chile, Canada, Hungary, Australia, Lithuania, Latvia, Estonia, Netherlands, Greece, Hong Kong
Eisai Inc.

Completed

Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures

Epilepsy

Greece, Italy, Spain, Sweden, Korea, Republic of, Germany, Australia, France, Switzerland, Slovakia, Poland, Taiwan, Hungary, Serbia, India, United Kingdom, Denmark, Russian Federation, South Africa, Montenegro
Eisai Co., Ltd.

Completed

A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures

Partial-onset Seizures

Korea, Republic of, Japan, Australia, China, Malaysia, Taiwan, Thailand
Hoffmann-La Roche

Completed

A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas

Basal Cell Carcinoma

United States, Spain, France, Germany, Netherlands, Russian Federation, Italy, Mexico, Austria, Canada
Eisai Inc.

Completed

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Refractory Partial Seizures

United States, France, Germany, Italy, United Kingdom, Belgium, Israel, South Africa, Finland, Russian Federation, Austria, Netherlands, Sweden, India
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma

Medulloblastoma | Nevoid Basal Cell Carcinoma Syndrome | Desmoplastic/Nodular Medulloblastoma | Medulloblastoma With Extensive Nodularity

United States, Canada, Puerto Rico, Australia
UCB Pharma GmbH

Completed

Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy (VICTOS)

Focal Epilepsy With and Without Secondary Generalization

Germany, Austria
UCB Biopharma SRL

Active, not recruiting

A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

United States, Australia, Belgium, France, Germany, Italy, Netherlands, Spain, United Kingdom
University of California, San Francisco
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Epilepsy Phenome/Genome Project (EPGP)

Epilepsy | Infantile Spasms | Lennox-Gastaut Syndrome | Polymicrogyria | Localization-related Epilepsy | Periventricular Heterotopias

United States, Argentina, Australia
Hoffmann-La Roche
Chugai Pharmaceutical Co.

Recruiting

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis (Cielo)

NMDAR Autoimmune Encephalitis | LGI1 Autoimmune Encephalitis

United States, Korea, Republic of, China, Japan, Czechia, Italy, Poland, Austria, Brazil, Argentina, Netherlands, Taiwan, France, Denmark, Ghana
ppharmaand GmbH
Bristol-Myers Squibb; Gynecologic Oncology Group; European Network of Gynaecological... and other collaborators

Active, not recruiting

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response

United States, United Kingdom, Korea, Republic of, Russian Federation, Canada, Denmark, Taiwan, New Zealand, Ireland, Japan, Spain, Australia, Israel, Italy, Greece, Sweden, Czechia, Finland, Poland, Belgium, Germany, Romania, Singa... and more
AstraZeneca
Merck Sharp & Dohme LLC; European Network of Gynaecological Oncological Trial... and other collaborators

Active, not recruiting

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Relapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive | BRCA Mutated

Korea, Republic of, France, China, Italy, United States, Israel, United Kingdom, Canada, Japan, Germany, Brazil, Netherlands, Belgium, Poland, Australia, Russian Federation, Spain

Clinical Trials on Jaw, Partially Edentulous in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations